Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 36Dermatologic 11Gastrointestinal 10Thoracic 8Gynecologic 7Sarcoma 5Breast 5Head & Neck 4CNS 3Plasma cell 2Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 47Lymphoma 15Prostatic Neoplasms 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

fludarabine phosphate 7Mycophenolic Acid 6Peripheral Blood Stem Cell Transplantation 5Cyclosporine 5Whole-Body Irradiation 4Cyclophosphamide 3Antilymphocyte Serum 3Tacrolimus 2Sunitinib 2Specimen Handling 2Methotrexate 2Busulfan 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1thymoglobulin 1temsirolimus 1sapanisertib 1relatlimab 1pertuzumab 1pazopanib 1palbociclib 1osimertinib 1orantinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Specimen Handling × Plasma cell × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04955808 2026-05-13

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

National Cancer Institute (NCI)

Suspended
2,400 enrolled
BreastGastrointestinalGenitourinaryPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡